Details for New Drug Application (NDA): 062238
✉ Email this page to a colleague
NDA 062238 describes DYCILL, which is a drug marketed by Glaxosmithkline and is included in two NDAs. Additional details are available on the DYCILL profile page.
The generic ingredient in DYCILL is dicloxacillin sodium. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dicloxacillin sodium profile page.
The generic ingredient in DYCILL is dicloxacillin sodium. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the dicloxacillin sodium profile page.
Summary for 062238
| Tradename: | DYCILL |
| Applicant: | Glaxosmithkline |
| Ingredient: | dicloxacillin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062238
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 250MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 500MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
